127 related articles for article (PubMed ID: 17803873)
1. Cytochrome P450 2D6 genotype variation and venlafaxine dosage.
McAlpine DE; O'Kane DJ; Black JL; Mrazek DA
Mayo Clin Proc; 2007 Sep; 82(9):1065-8. PubMed ID: 17803873
[TBL] [Abstract][Full Text] [Related]
2. Cytochrome P450 2D6 phenoconversion is common in patients being treated for depression: implications for personalized medicine.
Preskorn SH; Kane CP; Lobello K; Nichols AI; Fayyad R; Buckley G; Focht K; Guico-Pabia CJ
J Clin Psychiatry; 2013 Jun; 74(6):614-21. PubMed ID: 23541126
[TBL] [Abstract][Full Text] [Related]
3. Comparison of the pharmacokinetics of venlafaxine extended release and desvenlafaxine in extensive and poor cytochrome P450 2D6 metabolizers.
Preskorn S; Patroneva A; Silman H; Jiang Q; Isler JA; Burczynski ME; Ahmed S; Paul J; Nichols AI
J Clin Psychopharmacol; 2009 Feb; 29(1):39-43. PubMed ID: 19142106
[TBL] [Abstract][Full Text] [Related]
4. Understanding outliers on the usual dose-response curve: venlafaxine as a way to phenotype patients in terms of their CYP 2D6 status and why it matters.
Preskorn SH
J Psychiatr Pract; 2010 Jan; 16(1):46-9. PubMed ID: 20098230
[TBL] [Abstract][Full Text] [Related]
5. CYP2D6 genotype and venlafaxine-XR concentrations in depressed elderly.
Whyte EM; Romkes M; Mulsant BH; Kirshne MA; Begley AE; Reynolds CF; Pollock BG
Int J Geriatr Psychiatry; 2006 Jun; 21(6):542-9. PubMed ID: 16642541
[TBL] [Abstract][Full Text] [Related]
6. Hypotension caused by therapeutic doses of venlafaxine: case report and proposed pathophysiological mechanisms.
Alexandrino-Silva C; Nadalini Mauá FH; de Andrade AG; de Toledo Ferraz Alves TC
J Psychopharmacol; 2008 Mar; 22(2):214-6. PubMed ID: 18208934
[TBL] [Abstract][Full Text] [Related]
7. Comparisons of the efficacy and tolerability of extended-release venlafaxine, mirtazapine, and paroxetine in treatment-resistant depression: a double-blind, randomized pilot study in a Chinese population.
Fang Y; Yuan C; Xu Y; Chen J; Wu Z; Cao L; Yi Z; Hong W; Wang Y; Jiang K; Gao K; Cui X; Nierenberg AA;
J Clin Psychopharmacol; 2010 Aug; 30(4):357-64. PubMed ID: 20571433
[TBL] [Abstract][Full Text] [Related]
8. Does tachyphylaxis occur after repeated antidepressant exposure in patients with Bipolar II major depressive episode?
Amsterdam JD; Shults J
J Affect Disord; 2009 May; 115(1-2):234-40. PubMed ID: 18694599
[TBL] [Abstract][Full Text] [Related]
9. CYP2D6 polymorphism and clinical effect of the antidepressant venlafaxine.
Shams ME; Arneth B; Hiemke C; Dragicevic A; Müller MJ; Kaiser R; Lackner K; Härtter S
J Clin Pharm Ther; 2006 Oct; 31(5):493-502. PubMed ID: 16958828
[TBL] [Abstract][Full Text] [Related]
10. CYP2D6 genotype: impact on adverse effects and nonresponse during treatment with antidepressants-a pilot study.
Rau T; Wohlleben G; Wuttke H; Thuerauf N; Lunkenheimer J; Lanczik M; Eschenhagen T
Clin Pharmacol Ther; 2004 May; 75(5):386-93. PubMed ID: 15116051
[TBL] [Abstract][Full Text] [Related]
11. Efficacy and tolerability of venlafaxine extended release in patients with major depressive disorder.
Plesnicar BK
Psychiatr Danub; 2010 Sep; 22(3):413-7. PubMed ID: 20856184
[TBL] [Abstract][Full Text] [Related]
12. New antidepressants and the cytochrome P450 system: focus on venlafaxine, nefazodone, and mirtazapine.
Owen JR; Nemeroff CB
Depress Anxiety; 1998; 7 Suppl 1():24-32. PubMed ID: 9597349
[TBL] [Abstract][Full Text] [Related]
13. Venlafaxine XR in the treatment of anxiety.
Hackett D
Acta Psychiatr Scand Suppl; 2000; (406):30-5. PubMed ID: 11131468
[TBL] [Abstract][Full Text] [Related]
14. Extended-release venlafaxine in relapse prevention for patients with major depressive disorder.
Simon JS; Aguiar LM; Kunz NR; Lei D
J Psychiatr Res; 2004; 38(3):249-57. PubMed ID: 15003430
[TBL] [Abstract][Full Text] [Related]
15. Eight-week, placebo-controlled, double-blind comparison of the antidepressant efficacy and tolerability of bupropion XR and venlafaxine XR.
Hewett K; Chrzanowski W; Schmitz M; Savela A; Milanova V; Gee M; Krishen A; Millen L; Leary MO; Modell J
J Psychopharmacol; 2009 Jul; 23(5):531-8. PubMed ID: 18635695
[TBL] [Abstract][Full Text] [Related]
16. Paroxetine-induced conversion of cytochrome P450 2D6 phenotype and occurence of adverse effects.
Zourková A; Hadasová E
Gen Physiol Biophys; 2003 Mar; 22(1):103-13. PubMed ID: 12870705
[TBL] [Abstract][Full Text] [Related]
17. Rapid and reliable genotyping procedure for detection of alleles with mutations, deletion, or/and duplication of the CYP2D6 gene.
Arneth B; Shams M; Hiemke C; Härtter S
Clin Biochem; 2009 Aug; 42(12):1282-90. PubMed ID: 19393232
[TBL] [Abstract][Full Text] [Related]
18. Increased frequency of cytochrome P450 2D6 poor metabolizers among patients with metoprolol-associated adverse effects.
Wuttke H; Rau T; Heide R; Bergmann K; Böhm M; Weil J; Werner D; Eschenhagen T
Clin Pharmacol Ther; 2002 Oct; 72(4):429-37. PubMed ID: 12386645
[TBL] [Abstract][Full Text] [Related]
19. Bioequivalence of single and multiple doses of venlafaxine extended-release tablets and capsules in the fasted and fed states: four open-label, randomized crossover trials in healthy volunteers.
Wright CW; Aikman MS; Werts E; Seabolt J; Haeusler JM
Clin Ther; 2009 Nov; 31(11):2722-34. PubMed ID: 20110014
[TBL] [Abstract][Full Text] [Related]
20. Recognition of impaired atomoxetine metabolism because of low CYP2D6 activity.
ter Laak MA; Temmink AH; Koeken A; van 't Veer NE; van Hattum PR; Cobbaert CM
Pediatr Neurol; 2010 Sep; 43(3):159-62. PubMed ID: 20691935
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]